Table 2.1 Definitions of Selected Biopharmaceuticals
Table 2.2 Summary of Biotechnologies, 2009
Table 3.1 Global Pharmaceutical Biotech Sales Forecast ($bn), 2010-2016
Table 3.2 Global Pharmaceutical Biotech Sales Forecast ($bn), 2017-2025
Table 3.3 Leading Biotech Therapy Classes Sales Forecast ($bn), 2010-2016
Table 3.4 Leading Biotech Therapy Classes Sales Forecast ($bn), 2017-2025
Table 3.5 Market Shares (%) of the Leading Therapeutic Classes, 2009, 2015 and 2025
Table 3.6 Leading Biotech Drugs Sales Forecast ($m), 2010-2016
Table 3.7 Leading Biotech Drugs Sales Forecast ($m), 2017-2025
Table 3.8 Market Shares (%) of the Top Ten Drugs, 2009, 2015 & 2025
Table 4.1 Oncology Class Sales Forecast ($bn), 2010-2016
Table 4.2 Oncology Class Sales Forecast ($bn), 2017-2025
Table 4.3 Human Insulins Class Sales Forecast ($bn), 2010-2016
Table 4.4 Human Insulins Class Sales Forecast ($bn), 2017-2025
Table 4.5 Immunosuppressive Agents Class Sales Forecast ($bn), 2010-2016
Table 4.6 Immunosuppressive Agents Class Sales Forecast ($bn), 2017-2025
Table 4.7 Autoimmune Agents Class Sales Forecast ($bn), 2010-2016
Table 4.8 Autoimmune Agents Class Sales Forecast ($bn), 2017-2025
Table 4.9 Erythropoietin Products Class Sales Forecast ($bn), 2010-2016
Table 4.10 Erythropoietin Products Class Sales Forecast ($bn), 2017-2025
Table 4.11 Immunostimulating Agents Class Sales Forecast ($bn), 2010-2016
Table 4.12 Immunostimulating Agents Class Sales Forecast ($bn), 2017-2025
Table 4.13 Interferons Class Sales Forecast ($bn), 2010-2016
Table 4.14 Interferons Class Sales Forecast ($bn), 2017-2025
Table 4.15 Pure Vaccines Class Sales Forecast ($bn), 2010-2016
Table 4.16 Pure Vaccines Class Sales Forecast ($bn), 2017-2025
Table 4.17 Blood Coagulation Factors Class Sales Forecast ($bn), 2010-2016
Table 4.18 Blood Coagulation Factors Class Sales Forecast ($bn), 2017-2025
Table 4.19 Growth Hormones Class Sales Forecast ($bn), 2010-2016
Table 4.20 Growth Hormones Class Sales Forecast ($bn), 2017-2025
Table 4.21 Top 10 Classes, Rank Comparison, 2009, 2015 & 2025
Table 5.1 Enbrel Sales Forecast ($m), 2009-2016
Table 5.2 Enbrel Sales Forecast ($m), 2017-2025
Table 5.3 Remicade Sales Forecast ($m), 2010-2016
Table 5.4 Remicade Sales Forecast ($m), 2017-2025
Table 5.5 Avastin Sales Forecast ($m), 2009-2016
Table 5.6 Avastin Sales Forecast ($m), 20017-2025
Table 5.7 MabThera/Rituxan Sales Forecast ($m), 2009-2016
Table 5.8 MabThera/Rituxan Sales Forecast ($m), 2017-2025
Table 5.9 Humira Sales Forecast ($m), 2009-2016
Table 5.10 Humira Sales Forecast ($m), 2017-2025
Table 5.11 Herceptin Sales Forecast ($m), 2009-2016
Table 5.12 Herceptin Sales Forecast ($m), 2017-2025
Table 5.13 Lantus Sales Forecast ($m), 2009-2016
Table 5.14 Lantus Sales Forecast ($m), 2017-2025
Table 5.15 Neulasta Sales Forecast ($m), 2009-2016
Table 5.16 Neulasta Sales Forecast ($m), 2017-2025
Table 5.17 Glivec Sales Forecast ($m), 2009-2016
Table 5.18 Glivec Sales Forecast ($m), 2017-2024
Table 5.19 Epogen Sales Forecast ($m), 2009-2016
Table 5.20 Epogen Sales Forecast ($m), 2017-2025
Table 5.21 Top 10 Products: Ranked Comparison, 2009, 2015 & 2025
Table 6.1 The Top 10 Biotech Companies: Revenues ($m) and Market Shares (%), 2008
Table 7.1 SWOT Analysis of the Global Pharma Biotech Market, 2010-2025
Table 8.1 Global Market Shares (%) & Revenues ($m) by Region/Country, 2009
Table 8.2 Pharma Biotech Sales Forecast ($m) by Country/Region, 2010-2016
Table 8.3 Pharma Biotech Sales Forecast ($m) by Country/Region, 2017-2025
Table 8.4 Market Shares (%) by Country/Region, 2009, 2015 & 2025
Table 9.1 The Late-Stage Oncology Pipeline, 2009
Table 9.2 The Late-Stage Human Insulins Pipeline, 2009
Table 9.3 The Late-Stage Immunosuppressive Agents Pipeline, 2009
Table 9.4 The Late-Stage Autoimmune Agents Pipeline, 2009
Table 9.5 The Late-Stage Erythropoietin Products Pipeline, 2009
Table 9.6 The Late-Stage Immunostimulating Agents Pipeline, 2009
Table 9.7 The Late-Stage Interferons Pipeline, 2009
Table 9.8 The Late-Stage Pipeline for Pure Vaccines, 2009
Table 9.9 The Late-Stage Pipeline for Blood Coagulation Factors, 2009
Table 9.10 The Late-Stage Pipeline for Growth Hormones, 2009
Figure 3.1 Global Pharmaceutical Biotech Sales Forecast ($bn), 2010-2025
Figure 3.2 Leading Biotech Therapy Classes (Sales in $m), 2010-2025
Figure 3.3 Market Shares (%) of the Leading Therapy Classes, 2009
Figure 3.4 Market Shares (%) of the Leading Therapy Classes, 2015
Figure 3.5 Market Shares (%) of the Leading Therapy Classes, 2025
Figure 3.6 Top 10 Biotech Drugs Market Shares (%), 2009
Figure 3.7 Top 10 Biotech Drugs Market Shares (%), 2015
Figure 3.8 Top Ten Biotech Drugs Market Shares (%), 2025
Figure 4.1 Oncology Class Sales Forecast ($bn), 2010-2025
Figure 4.2 Human Insulins Class Sales Forecast ($bn), 2010-2025
Figure 4.3 Immunosuppressive Agents Class Sales Forecast ($bn), 2010-2025
Figure 4.4 Autoimmune Agents Class Sales Forecast ($bn), 2010-2025
Figure 4.5 Erythropoietin Products Class Sales Forecast ($bn), 2010-2025
Figure 4.6 Immunostimulating Agents Class Sales Forecast ($bn), 2010-2025
Figure 4.7 Interferons Class Sales Forecast ($bn), 2010-2025
Figure 4.8 Pure Vaccines Class Sales Forecast ($bn), 2010-2025
Figure 4.9 Blood Coagulation Factors Class Sales Forecast ($bn), 2010-2025
Figure 4.10 Growth Hormones Class Sales Forecast ($bn), 2010-2025
Figure 4.11 Top Ten Therapy Classes Sales ($bn), 2009, 2015 & 2025
Figure 5.1 Enbrel Sales Forecast ($m), 2010-2025
Figure 5.2 Remicade Sales Forecast ($m), 2010-2025
Figure 5.3 Avastin Sales Forecast ($m), 2010-2025
Figure 5.4 MabThera/Rituxan Sales Forecast ($m), 2010-2025
Figure 5.5 Humira Sales Forecast ($m), 2010-2025
Figure 5.6 Herceptin Sales Forecast ($m), 2010-2025
Figure 5.7 Lantus Sales Forecast ($m), 2010-2025
Figure 5.8 Neulasta Sales Forecast ($m), 2010-2025
Figure 5.9 Glivec Sales Forecast ($m), 2010-2025
Figure 5.10 Epogen Sales Forecast ($m), 2010-2025
Figure 5.11 Top Ten Biotech Drugs Sales ($m), 2009, 2015 & 2025
Figure 6.1 The Top Ten Biotech Companies, Revenues ($m), 2008
Figure 6.2 The Top Ten Biotech Companies, Market Shares (%), 2008
Figure 8.1 Pharma Biotech Market Shares (%) by Country/Region, 2009
Figure 8.2 Pharma Biotech Market Shares (%) by Country/Region, 2015
Figure 8.3 Pharma Biotech Market Shares (%) by Country/Region, 2025
[Tabellenverzeichnis ausblenden]
